Eli Lilly's Olumiant receives expanded alopecia indication for children 12 and up

source: news (news:seeking-alpha)published 2026-09-25 21:56ingested 2026-09-26 02:49

retained text

Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in

Eli Lilly's Olumiant receives expanded alopecia indication for children 12 and up

Sep 25, 2026, 5:56 PM ETEli Lilly and Company (LLY) StockBy : Jonathan Block, SA News Editor

The US FDA expanded the use of Eli Lilly's (LLY) Olumiant (baricitinib) for severe alopecia areata to include children 12 years and older.

Approval was based on 36-week data from the adolescent cohort of the phase 3 BRAVE-AA-PEDS study that

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Recommended For You

document fetched 2026-09-26 02:49 · canonical https://seekingalpha.com/news/4647363-eli-lilly-olumiant-receives-expanded-alopecia-indication-children-12-and-up?feed_item_type=news